Molecular Weight(MW): 358.43
Prednisone (Adasone) is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound.
Purity & Quality Control
Choose Selective Glucocorticoid Receptor Inhibitors
|Description||Prednisone (Adasone) is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound.|
Prednisone blocks Peripheral blood lymphocytes (PBL) growth in the G1 phase of cell cycle and inhibits both IL-2 receptor (IL-2R) expression and IL-2 secretion in activated human peripheral blood T lymphocytes. Prednisone increases apoptosis in PHA-activated human PBL, and the apoptotic effect of Prednisone is stronger on CD8(+) than on CD4(+) T lymphocytes. 
|In vivo||Prednisone-treated rats show a significant delay of 20% in learning and memory retention in rats as compared with controls.  Prednisone results in reduced weight gain, unchanged alter uterine weight, lowered serum magnesium (Mg), unchange serum calcium (Ca), phosphate (P), 25-hydroxyvitamin D (25OHD), or 1,25-dihydroxyvitamin D [1,25(OH)2D], striking increased in calcified cartilage, reduced cross-sectional area and cortical area, unchange medullary area of the tibial diaphysis, lowered periosteal and endocortical bone formation and apposition rates, increased mean cancellous bone area and cancellous bone perimeter of the tibial metaphysis in both sham-operated and ovariectomized rats.  Prednisone-treated rabbit shows a 30% reduction in percent stenosis, a 35% decrease in neointimal area, and a 66% decrement in neointimal thickness.  Prednisone treatment significantly reduces the level of TGF-beta1 and HYP in diaphragm from mdx mice to values similar to control mice, but results in a higher level of the HP cross-link compared with untreated mdx mice. |
-  Lanza L, et al. Clin Exp Immunol, 1996, 103(3), 482-490.
-  Ramos-Remus C, et al. J Investig Med, 2002, 50(6), 458-464.
-  Turner RT, et al. Calcif Tissue Int, 1995, 56(4), 311-315.
|In vitro||DMSO||71 mg/mL (198.08 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT01553188||Active, not recruiting||Prostatic Neoplams|Prostate Cancer|Neoplasm, Prostate|Neoplasm,Prostatic||National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)||February 7, 2012||Phase 2|
|NCT03036904||Not yet recruiting||Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma||Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center||February 6, 2017||Phase 1|
|NCT01683994||Recruiting||Prostatic Neoplasms||National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)||September 6, 2012||Phase 1|Phase 2|
|NCT01331018||Recruiting||Fanconi Anemia||Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)||February 22, 2012||Phase 1|
|NCT02403505||Not yet recruiting||Stage, Prostate Cancer|Surgery||Dr. Han Xu, President/CEO / PD / PI / Monitor / IRB Chair|PPD|Medicine Invention Design, Inc||August 2020||Phase 3|
|NCT02899026||Not yet recruiting||Polymyalgia Rheumatica||GlaxoSmithKline||June 2017||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.